Malnutrition in obesity · screening

Malnutrition in Obesity: Screening the Patient a BMI Hides

Malnutrition in obesity is diagnosed at any BMI under the GLIM criteria, for example reduced muscle mass plus inflammation. The usual screens miss it: among older outpatients with a BMI of 25 or more, 58.8% of those malnourished passed the short-form screen.

A patient can carry excess fat and still lack the muscle, protein and micronutrients that recovery depends on. The screens most practices use were never designed to see that combination.

Malnutrition in obesity is a diagnosis the chart is built to miss. Every tool that opens the workup keys on weight loss and thinness, so the heavy patient sails through clean while sarcopenic wasting, active metaflammation and empty micronutrient stores go unrecorded.

The Global Leadership Initiative on Malnutrition (GLIM) never required a low weight. Its 2019 consensus asks for one phenotypic criterion (non-volitional weight loss, low BMI or reduced muscle mass) plus one etiologic criterion (reduced intake or assimilation, or inflammation and disease burden). Reduced muscle mass with inflammation is a complete diagnosis at any BMI. The 2025 five-year update kept that structure, left the choice of muscle-mass method to the technology a site has, allowed clinical judgment to satisfy the inflammation criterion, and named malnutrition in obesity as one of its open priorities. The criteria were never the obstacle. The habit of reading BMI as a proxy for nourishment is.

Why the usual screen clears the patient with obesity

GLIM is a two-step process: screen, then assess. The failure sits in the first step. Among 264 geriatric outpatients with a BMI of 25 or more, GLIM-defined malnutrition was present in 30.3% and sarcopenic obesity in 15.9%. More than half of the malnourished patients, 58.8%, were not at risk on the Mini Nutritional Assessment Short Form, the screen that would have sent them on to assessment. Among the patients that short form cleared, malnutrition ran 42.9% in those with sarcopenic obesity against 18.7% in those without. Where sarcopenic obesity and malnutrition coexisted, the odds ratio for frailty was 5.11, independent of age and comorbidity.

The pattern holds at higher weights. In adults with advanced knee osteoarthritis and a BMI of 35 or more, averaging a BMI of 42.4, 26.1% met GLIM criteria through low muscle mass on DXA plus elevated C-reactive protein, 26.1% had sarcopenic obesity, and 13% had both. These are the patients queued for joint replacement, and nothing in a weight-based intake flags them.

Sarcopenic obesity is a muscle diagnosis, not a weight diagnosis

The ESPEN and EASO consensus defines sarcopenic obesity as excess adiposity coexisting with low muscle mass or function. Screening begins with an elevated BMI or waist circumference plus suspicion of low muscle mass or function from risk factors, symptoms or a validated questionnaire. Diagnosis then runs in order: muscle function first, body composition second. Stage I carries no complications; Stage II carries complications linked to altered body composition or muscle dysfunction.

The consensus traces the condition to sedentary metabolic change, adipose tissue derangement, comorbid disease and aging, and those pieces run as a chain. Inflamed, insulin-resistant adipose tissue is the first driver, keeping a low-grade inflammatory signal running through the whole body. Muscle is the second: pain and fatigue cut movement, unloaded muscle wastes, and the patient loses glucose-disposal capacity while fat mass holds or grows. The third driver is economic. A food supply engineered around acellular carbohydrates and industrial seed oils sells calories far more readily than protein and micronutrients, so stored fuel rises while structural stores fall, and the scale records only the first half of that trade. Muscle and fat distribution also track neurodegenerative risk, which is set out in how body fat distribution relates to dementia.

The micronutrient layer follows inflammation

Among the first 200 adults evaluated for bariatric surgery at a hospital in Turin, 85.5% had at least one micronutrient deficiency, led by vitamin D at 74.5%, folate at 33.5% and iron at 32%. C-reactive protein was above 5 mg/L in 65% of them. After adjustment, elevated CRP carried an odds ratio of 5.84 for B12 deficiency and 4.02 for folate deficiency. Inflammation is therefore doing two jobs in the same patient: it satisfies a GLIM etiologic criterion, and it predicts which stores are empty. A high-sensitivity CRP on the draw both supports the diagnosis and tells you where to look next.

Why it matters in the operating room and on a GLP-1 prescription

Obesity alone is not the surgical hazard; muscle loss inside obesity is. Across 27,057 craniotomies in the American College of Surgeons NSQIP database, a sarcopenic-obese phenotype built from BMI and serum albumin carried an odds ratio of 2.28 for 30-day mortality, while the obese-replete phenotype showed no mortality increase at 1.06. Among 2,908 UK Biobank participants who went on to major abdominal cancer surgery, the 100 with sarcopenic obesity had a hazard ratio of 6.44 for death at 30 days and 3.61 at 90 days, with 27% longer hospital stays and 83% longer intensive care stays, yet no significant excess of complications (odds ratio 0.79).

That finding inverts the usual preoperative logic. These patients did not have more complications. They had less reserve to survive the ones they had. A complication audit will never surface them, a BMI will actively reassure you, and the obesity paradox is really a muscle story: fat with muscle behind it survived, fat without it did not. Only a measurement of muscle separates the two before the first incision.

Weight-loss therapy opens a second road into the same phenotype. In twenty randomized trials with 15,782 participants whose body composition was measured by DXA or MRI, lean mass made up 25% to 39% of the weight lost on incretin agonists, 35.2% on semaglutide, and a comparable 26.2% with lifestyle intervention alone. Lifestyle plus resistance training had the smallest lean share, 17.5%. A chart tracking weight, A1c and blood pressure can improve on every line while a patient with marginal muscle crosses into sarcopenic obesity. Resistance training and adequate protein are the treatment, because loaded muscle is the tissue that keeps its claim on amino acids during an energy deficit; body composition monitoring is how anyone knows whether they worked.

State the evidence tier plainly: this is consensus and observational data, not a randomized trial of GLIM-guided optimization. Trials isolate one disease and exclude the inflamed, multimorbid patient with obesity, so that patient will not be handed to you as a trial result. Measure the mechanism in the patient in front of you. The patient-facing version of the preoperative window is nutrition before surgery and what to measure.

Who to screen and what a finding changes

Adults with obesity scheduled for elective joint, spine or abdominal surgery, screened alongside the glycemia work in preoperative diabetes screening before surgery.
Patients about to start incretin therapy, with a repeat once weight loss is established.
Older adults with an overweight or obese BMI who have slowed down, fallen or report new fatigue, whatever a short-form screen said.
Patients with persistently elevated CRP or a long history of restrictive dieting and regain.

Write those triggers into your selection criteria and standing orders so the screen does not depend on whether a patient looks thin.

Measura [Cardiometabolic and Autonomic Health Analysis] supplies the objective half of the workup; it does not diagnose or treat malnutrition. Bioimpedance body composition reports skeletal muscle mass, fat mass and segmental distribution, the body-composition step the sarcopenic obesity algorithm calls for after muscle function is tested in your office. Laboratory panels can place high-sensitivity CRP, ferritin, B12, zinc and red blood cell magnesium beside fasting insulin; vitamin D, folate and albumin come from blood work you order. Indirect calorimetry measures resting energy expenditure, which is interpretable only against the lean mass figure from the same visit and gives a protein and energy plan a measured denominator.

A finding changes management in three ways. A GLIM diagnosis built on low muscle mass documents malnutrition in a chart that says obesity, which moves nutritional optimization ahead of the operating date. A lean-mass baseline before incretin therapy turns muscle preservation from advice into an endpoint with a retest date. And sarcopenic obesity in an older adult belongs in the fall-risk work already structured at the annual wellness visit, next to cognitive assessment and fall prevention. Unmeasured is unmanaged. The patient-facing version, for someone told they cannot be malnourished at their weight, is can you be overweight and malnourished.

Frequently asked questions

Can a patient with obesity meet GLIM criteria for malnutrition?

A patient with obesity meets GLIM criteria when reduced muscle mass coexists with reduced intake or with inflammation and disease burden; low BMI is only one of three phenotypic options. The 2025 update leaves the muscle-mass method to the resources a site has. The parallel problem of fat distribution hiding behind a normal BMI is covered in visceral adiposity screening beyond BMI.

Why not rely on a short nutrition screen in heavier patients?

Short screens lean on weight loss and appetite, so they under-call patients who have not lost weight. In 264 older outpatients with a BMI of 25 or more, 58.8% of those with GLIM-defined malnutrition were not at risk on the short form. Pairing the screen with a body composition measurement closes that gap, and standing orders that make screening reproducible keep it closed.

How much of the weight lost on incretin therapy is muscle?

In pooled randomized trials using DXA or MRI, lean mass was 25% to 39% of the weight lost on incretin agonists, similar to lifestyle-only weight loss, and 17.5% when resistance training was added. The share varies between patients, so a baseline and a repeat measurement matter. Why energy expenditure should be measured rather than estimated in the same patients is laid out in measured versus estimated metabolic rate.

Which micronutrients deserve attention when obesity comes with inflammation?

Before bariatric surgery, vitamin D, folate and iron deficiencies were the most common in one Italian series, and an elevated CRP raised the odds of B12 and folate deficiency. In patients taking metformin, a serum B12 alone can mislead; the functional markers worth adding are described in metformin B12 deficiency screening.

Does sarcopenic obesity belong in fall-risk screening?

Sarcopenic obesity together with malnutrition raised the odds of frailty and of disability in instrumental activities of daily living in older adults with an elevated BMI. Low muscle mass and function belong in the fall-risk assessment, and vitamin D status sits in the same conversation, as discussed in vitamin D screening indications and falls risk.

Put muscle on the preoperative checklist

See how the Measura protocol adds body composition, nutrient laboratory panels and measured metabolic rate to a referral or standing-order workflow.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Cederholm, T., Jensen, G. L., Correia, M. I. T. D., Gonzalez, M. C., Fukushima, R., Higashiguchi, T., et al. (2019). GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. Clinical Nutrition, 38(1), 1-9. https://doi.org/10.1016/j.clnu.2018.08.002
Cederholm, T., Jensen, G. L., Correia, M. I. T. D., Gonzalez, M. C., Fukushima, R., Pisprasert, V., et al. (2025). The GLIM consensus approach to diagnosis of malnutrition: A 5-year update. Clinical Nutrition, 49, 11-20. https://doi.org/10.1016/j.clnu.2025.03.018
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., et al. (2022). Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clinical Nutrition, 41(4), 990-1000. https://doi.org/10.1016/j.clnu.2021.11.014
Kayhan Kocak, F. O., Altın, Z., & Kızıltaş, A. (2026). Malnutrition by GLIM and its overlap with sarcopenic obesity in older adults with elevated body mass index: A retrospective cross-sectional study. Nutrition in Clinical Practice, 41(3), 799-810. https://doi.org/10.1002/ncp.70086
Vieira, F. T., Godziuk, K., Barazzoni, R., Batsis, J. A., Cederholm, T., Donini, L. M., et al. (2025). Hidden malnutrition in obesity and knee osteoarthritis: Assessment, overlap with sarcopenic obesity and health outcomes. Clinical Nutrition, 48, 111-120. https://doi.org/10.1016/j.clnu.2025.03.019
Pellegrini, M., Rahimi, F., Boschetti, S., Devecchi, A., De Francesco, A., Mancino, M. V., et al. (2021). Pre-operative micronutrient deficiencies in patients with severe obesity candidates for bariatric surgery. Journal of Endocrinological Investigation, 44(7), 1413-1423. https://doi.org/10.1007/s40618-020-01439-7
Roach, C. S., Wertheimer, B., Shah, K. H., Lu, V. M., Shah, A. H., & Komotar, R. J. (2026). Sarcopenic obesity and cachexia as nutritional risk phenotypes and histology-specific outcomes after intracranial tumor resection: a histology-stratified NSQIP analysis of 27,057 cases. Neurosurgical Review, 49(1). https://doi.org/10.1007/s10143-026-04450-3
Chou, W. K., Guidozzi, N., Giorgi, L., Salem, R., & Markar, S. R. (2026). Impact of sarcopenic obesity on outcomes following major abdominal cancer surgery: A population-based observational study. European Journal of Surgical Oncology, 52(4), 111505. https://doi.org/10.1016/j.ejso.2026.111505
Eisa, N., & Barood, O. (2026). Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity & Metabolism, 28(6), 4818-4827. https://doi.org/10.1111/dom.70666